Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Strategy Leadership

Samsung Bioepis Opens New HQ To Drive Next-Generation Biosimilars

New Site In Songdo Includes Lab And Office Space

  • News

Executive Summary

With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.

You may also be interested in...



Samsung Bioepis Moves Swiftly To Denosumab Phase III

Samsung Bioepis has announced that its SB16 biosimilar denosumab rival to Amgen’s Prolia has progressed to Phase III trials.

Samsung Bioepis First To File EU Lucentis Rival

Samsung Bioepis has beaten its rivals to become the first firm to announce successful filing of a ranibizumab biosimilar rival to Lucentis in the EU.

Samsung BioLogics’ 'Super Plant' Reflects Robust Global COVID-19 R&D

Samsung BioLogics’ construction of a fourth, large-scale manufacturing plant reflects increasing orders amid robust global COVID-19 R&D activities and further cements the Korean firm's position as the world's biggest contract biologics producer. 

Table

View full table

Related Content

Generics Bulletin

Topics

Related Companies

Tags:
Biosimilars Strategy Leadership
Latest Headlines

BioFactura Completes Phase I For Late-To-Market Stelara Biosimilar

Glenmark Divests API Company, Setting Out On Distinct Journeys

Takeda Pens Mid-Trial Settlement To Dismiss US Colcrys Antitrust Suit

Generics Savings Once Again Could Help A Major US Health Care Reform Bill

See All
UsernamePublicRestriction

Register

GB150609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By